UBS Group’s NervGen Pharma NGEN Stock Holding History

UBS Group’s Portfolio NGEN Stock Details NGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$782K	Buy	379,726 +318,209	+517%	+$987K	﹤0.01%	5923
2026 Q1	$232K	Buy	+61,517	New	+$266K	﹤0.01%	6550

Other funds holding NGEN

EAM

Empery Asset Management New York $86.5M AUM

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

GCM

Ghisallo Capital Management Boston, Massachusetts $5.1B AUM 39.13% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

UBS Group's NGEN Position: Q2 2026 in Review

UBS Group increased its NervGen Pharma (NGEN) stake by 517% in Q2 2026, buying an estimated $987K and bringing the position to 379,726 shares worth $782K. The position accounts for ﹤0.01% of the portfolio, ranked #5923.

UBS Group first reported a position in NGEN in Q1 2026 and has held it in 2 quarters since. 62 funds tracked by Wall St. Rank hold NGEN as of Q2 2026.

UBS Group held 379,726 shares of NervGen Pharma worth $782K as of Q2 2026.
UBS Group bought 318,209 NervGen Pharma shares in Q2 2026, an estimated $987K.
NervGen Pharma made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5923 holding.
UBS Group first reported a position in NervGen Pharma in Q1 2026 and has held it in 2 quarters since.
62 funds tracked by Wall St. Rank held NervGen Pharma as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.